Effect of raloxifen on kidney function in post menopausal women with diabetic nephropathy
Not Applicable
- Conditions
- Diabetic Nephropathy.E10, E11,
- Registration Number
- IRCT138904151179N4
- Lead Sponsor
- Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
Inclusion Criteria : confirmed menopause (last period of the patient over the past year and FSH levels is more than 25mu/L, Age less than 70 years, confirmed albuminuria due to DM (ACR> 30mg/gr)
Exclusion criteria: History of Treatment with estrogen or SERM in the past six months, a personal history of breast or Genicologic cancer, History of thrombotic disorders, GFR less than 30 mL/min, hypertriglyceridemia over than 400 mg/dl, Active liver disease, intolerance to raloxifene or other Allergic reactions
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Albuminuryia. Timepoint: at the begining of the study and 4month after intervention. Method of measurement: Nephelometry.
- Secondary Outcome Measures
Name Time Method ipid profile(TG, Cholesterol, HDL-C). Timepoint: at the begining of the study and 4month after intervention. Method of measurement: Enzymatic methods.;Blood pressure. Timepoint: at the begining of the study and 2&4 month after intervention. Method of measurement: standard methods checking for BP.;HbA1c. Timepoint: at the beginning of the study and 4 months after intervention. Method of measurement: lone exchange.